Home › Funds › Eversept Partners, LP › NAMS

Eversept Partners, LP position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

Eversept Partners, LP reported holding 275,471 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$9.3M, representing 0.49% of its reported portfolio and ranking #50 among its reported holdings. Eversept Partners, LP has disclosed NAMS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)275.47K sh
Reported value held$9.34M
Portfolio Weight0.49%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Eversept Partners, LP's NAMS position evolved

Eversept Partners, LP first disclosed a stake in NAMS in Q3 2023 at 660,618 shares (US$6.1M). The position peaked in Q4 2025 at 420,827 shares, worth US$14.8M. Across 12 filings, Eversept Partners, LP increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 275,471 shares valued at US$9.3M — a reduction of -10,293 shares quarter over quarter.. Notable position changes include a 43% trim in Q4 2023 (shares rose 114% over the following quarter), a 48% increase in Q2 2025 (shares rose 50% over the following quarter), a 32% trim in Q1 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 660.62K $6.11M New
Q4 2023 374.40K $4.18M Reduce
Q1 2024 353.96K $8.37M Reduce
Q2 2024 329.89K $6.34M Reduce
Q3 2024 307.36K $5.10M Reduce
Q4 2024 275.36K $7.08M Reduce
Q1 2025 280.95K $5.75M Add
Q2 2025 414.43K $7.51M Add
Q3 2025 488.59K $13.90M Add
Q4 2025 420.83K $14.76M Reduce
Q1 2026 285.76K $9.15M Reduce
Q2 2026 275.47K $9.34M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 44 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Eversept Partners, LP held NAMS?

Eversept Partners, LP has disclosed NAMS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Eversept Partners, LP's current position in NAMS?

As of Q2 2026, Eversept Partners, LP holds 275.47K shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $9.34M, representing 0.49% of its reported portfolio and ranking #50.

Has Eversept Partners, LP been buying or selling NAMS?

In the latest 13F filing (Q2 2026), Eversept Partners, LP reduced its position in NAMS. The position peaked in Q4 2025 at 420.83K shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.